메뉴 건너뛰기




Volumn 55, Issue 5, 2010, Pages 536-549

Nuclear receptor-mediated induction of CYP450 by antiretrovirals: Functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans

Author keywords

antiretroviral therapy; CYP450; drug interactions; HIV protease inhibitor; polymorphism; PXR

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DARUNAVIR; EFAVIRENZ; FOSAMPRENAVIR; LOPINAVIR; NELFINAVIR; PREGNANE X RECEPTOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

EID: 78650210692     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181f52f0c     Document Type: Article
Times cited : (70)

References (72)
  • 1
    • 51849107500 scopus 로고    scopus 로고
    • Drug interactions involving combination antiretroviral therapy and other anti-infective agents: Repercussions for resource-limited countries
    • Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis. 2008;7: 948-961.
    • (2008) J Infect Dis , vol.7 , pp. 948-961
    • Dooley, K.E.1    Flexner, C.2    Andrade, A.S.3
  • 2
    • 33846886738 scopus 로고    scopus 로고
    • PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine
    • Li T, Chen W, Chiang JY. PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J Lipid Res. 2007;2:373-384.
    • (2007) J Lipid Res , vol.2 , pp. 373-384
    • Li, T.1    Chen, W.2    Chiang, J.Y.3
  • 3
    • 39749171761 scopus 로고    scopus 로고
    • Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response
    • Moreau A, Vilarem MJ, Maurel P, et al. Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol Pharm. 2008;1:35-41.
    • (2008) Mol Pharm , vol.1 , pp. 35-41
    • Moreau, A.1    Vilarem, M.J.2    Maurel, P.3
  • 4
    • 0035823528 scopus 로고    scopus 로고
    • Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR
    • Dussault I, Lin M, Hollister K, et al. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem. 2001;36: 33309-33312.
    • (2001) J Biol Chem , vol.36 , pp. 33309-33312
    • Dussault, I.1    Lin, M.2    Hollister, K.3
  • 5
    • 0035987895 scopus 로고    scopus 로고
    • CYP3A4 induction by drugs: Correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes
    • Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002;7: 795-804.
    • (2002) Drug Metab Dispos , vol.7 , pp. 795-804
    • Luo, G.1    Cunningham, M.2    Kim, S.3
  • 6
    • 0035029345 scopus 로고    scopus 로고
    • Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors
    • Huang L, Wring SA, Woolley JL, et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos. 2001;5:754-760.
    • (2001) Drug Metab Dispos , vol.5 , pp. 754-760
    • Huang, L.1    Wring, S.A.2    Woolley, J.L.3
  • 7
    • 44149109915 scopus 로고    scopus 로고
    • Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: Studies with anti-human immunodeficiency virus protease inhibitors
    • Gupta A, Mugundu GM, Desai PB, et al. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab Dispos. 2008;6: 1172-1180.
    • (2008) Drug Metab Dispos , vol.6 , pp. 1172-1180
    • Gupta, A.1    Mugundu, G.M.2    Desai, P.B.3
  • 8
    • 6344240478 scopus 로고    scopus 로고
    • Induction of CYP3A4 by efavirenz in primary human hepatocytes: Comparison with rifampin and phenobarbital
    • Hariparsad N, Nallani SC, Sane RS, et al. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004;11:1273-1281.
    • (2004) J Clin Pharmacol , vol.11 , pp. 1273-1281
    • Hariparsad, N.1    Nallani, S.C.2    Sane, R.S.3
  • 9
    • 15244350599 scopus 로고    scopus 로고
    • Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients
    • Fellay J, Marzolini C, Decosterd L, et al. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol. 2005;12:865-873.
    • (2005) Eur J Clin Pharmacol , vol.12 , pp. 865-873
    • Fellay, J.1    Marzolini, C.2    Decosterd, L.3
  • 10
    • 0034785945 scopus 로고    scopus 로고
    • The human pregnane X receptor: Genomic structure and identification and functional characterization of natural allelic variants
    • Zhang J, Kuehl P, Green ED, et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001;7:555-572.
    • (2001) Pharmacogenetics , vol.7 , pp. 555-572
    • Zhang, J.1    Kuehl, P.2    Green, E.D.3
  • 11
    • 34247624633 scopus 로고    scopus 로고
    • Identification of NR1I2 genetic variation using resequencing
    • King CR, Xiao M, Yu J, et al. Identification of NR1I2 genetic variation using resequencing. Eur J Clin Pharmacol. 2007;6:547-554.
    • (2007) Eur J Clin Pharmacol , vol.6 , pp. 547-554
    • King, C.R.1    Xiao, M.2    Yu, J.3
  • 12
    • 37549010733 scopus 로고    scopus 로고
    • Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression
    • Lamba J, Lamba V, Strom S, et al. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos. 2008;1: 169-181.
    • (2008) Drug Metab Dispos , vol.1 , pp. 169-181
    • Lamba, J.1    Lamba, V.2    Strom, S.3
  • 13
    • 0034777488 scopus 로고    scopus 로고
    • Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4
    • Hustert E, Zibat A, Presecan-Siedel E, et al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos. 2001;11:1454-1459.
    • (2001) Drug Metab Dispos , vol.11 , pp. 1454-1459
    • Hustert, E.1    Zibat, A.2    Presecan-Siedel, E.3
  • 14
    • 53349160769 scopus 로고    scopus 로고
    • Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-.T) with reduced concentrations of unboosted atazanavir
    • Siccardi M, D'Avolio A, Baietto L, et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-.T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis. 2008;9:1222-1225.
    • (2008) Clin Infect Dis , vol.9 , pp. 1222-1225
    • Siccardi, M.1    D'Avolio, A.2    Baietto, L.3
  • 15
    • 19944428456 scopus 로고    scopus 로고
    • Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study
    • Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400.
    • (2004) AIDS , vol.18 , pp. 2391-2400
    • Haas, D.W.1    Ribaudo, H.J.2    Kim, R.B.3
  • 16
    • 15944414161 scopus 로고    scopus 로고
    • An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children
    • Saitoh A, Singh KK, Powell CA, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS. 2005;4:371-380.
    • (2005) AIDS , vol.4 , pp. 371-380
    • Saitoh, A.1    Singh, K.K.2    Powell, C.A.3
  • 17
    • 0037022006 scopus 로고    scopus 로고
    • Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study
    • Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;9300:30-36.
    • (2002) Lancet , vol.9300 , pp. 30-36
    • Fellay, J.1    Marzolini, C.2    Meaden, E.R.3
  • 18
    • 27944460707 scopus 로고    scopus 로고
    • Pharmacogenetics of long-term responses to antiretroviral regimens containing eavirenz and/or nelfinavir: An Adult Aids Clinical Trials Group Study
    • Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing eavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005;11: 1931-1942.
    • (2005) J Infect Dis , vol.11 , pp. 1931-1942
    • Haas, D.W.1    Smeaton, L.M.2    Shafer, R.W.3
  • 19
    • 17644414659 scopus 로고    scopus 로고
    • Influence of 516G.T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects
    • Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G.T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis. 2005;9:1358-1361.
    • (2005) Clin Infect Dis , vol.9 , pp. 1358-1361
    • Rodriguez-Novoa, S.1    Barreiro, P.2    Rendon, A.3
  • 20
    • 20244364148 scopus 로고    scopus 로고
    • Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
    • Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;1:1-5.
    • (2005) Pharmacogenet Genomics , vol.1 , pp. 1-5
    • Rotger, M.1    Colombo, S.2    Furrer, H.3
  • 21
    • 26244454187 scopus 로고    scopus 로고
    • Functional analysis of four naturally occurring variants of human constitutive androstane receptor
    • Ikeda S, Kurose K, Jinno H, et al. Functional analysis of four naturally occurring variants of human constitutive androstane receptor. Mol Genet Metab. 2005;1-2:314-319.
    • (2005) Mol Genet Metab , vol.1-2 , pp. 314-319
    • Ikeda, S.1    Kurose, K.2    Jinno, H.3
  • 22
    • 32044444072 scopus 로고    scopus 로고
    • The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease
    • Dring MM, Goulding CA, Trimble VI, et al. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology. 2006;2:341-348.
    • (2006) Gastroenterology , vol.2 , pp. 341-348
    • Dring, M.M.1    Goulding, C.A.2    Trimble, V.I.3
  • 23
    • 33747085521 scopus 로고    scopus 로고
    • Cyp3A4 Cyp3A5 and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients
    • Roy JN, Barama A, Poirier C, et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics. 2006;9:659-665.
    • (2006) Pharmacogenet Genomics , vol.9 , pp. 659-665
    • Roy, J.N.1    Barama, A.2    Poirier, C.3
  • 24
    • 0034948077 scopus 로고    scopus 로고
    • Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
    • Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001;5:399-415.
    • (2001) Pharmacogenetics , vol.5 , pp. 399-415
    • Lang, T.1    Klein, K.2    Fischer, J.3
  • 25
    • 49649103848 scopus 로고    scopus 로고
    • The steady-state pharmaco-kinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors
    • von HN, Babacan E, Lennemann T, et al. The steady-state pharmaco-kinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother. 2008;3: 579-582.
    • (2008) J Antimicrob Chemother , vol.3 , pp. 579-582
    • Von Hn Babacan, E.1    Lennemann, T.2
  • 26
    • 33847672711 scopus 로고    scopus 로고
    • Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers
    • Sekar VJ, Lefebvre E, De PE, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother. 2007;3:958-961.
    • (2007) Antimicrob Agents Chemother , vol.3 , pp. 958-961
    • Sekar, V.J.1    Lefebvre, E.2    De, P.E.3
  • 27
    • 34548299142 scopus 로고    scopus 로고
    • Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers
    • Luber AD, Brower R, Kim D, et al. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med. 2007;7:457-464.
    • (2007) HIV Med , vol.7 , pp. 457-464
    • Luber, A.D.1    Brower, R.2    Kim, D.3
  • 28
    • 0034801355 scopus 로고    scopus 로고
    • Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers
    • Saah AJ, Winchell GA, Nessly ML, et al. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob Agents Chemother. 2001;10:2710-2715.
    • (2001) Antimicrob Agents Chemother , vol.10 , pp. 2710-2715
    • Saah, A.J.1    Winchell, G.A.2    Nessly, M.L.3
  • 29
    • 41849146368 scopus 로고    scopus 로고
    • Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir
    • Klein CE, Chiu YL, Cai Y, et al. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir. J Clin Pharmacol. 2008;5:553-562.
    • (2008) J Clin Pharmacol , vol.5 , pp. 553-562
    • Klein, C.E.1    Chiu, Y.L.2    Cai, Y.3
  • 30
    • 25144491177 scopus 로고    scopus 로고
    • The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients
    • Justesen US, Hansen IM, Andersen AB, et al. The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients. HIV Med. 2005;5: 334-340.
    • (2005) HIV Med , vol.5 , pp. 334-340
    • Justesen, U.S.1    Hansen, I.M.2    Andersen, A.B.3
  • 31
    • 33750570685 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir
    • Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;3:278-283.
    • (2006) J Acquir Immune Defic Syndr , vol.3 , pp. 278-283
    • Kearney, B.P.1    Mathias, A.2    Mittan, A.3
  • 32
    • 27844564302 scopus 로고    scopus 로고
    • Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers
    • Bittner B, Riek M, Holmes B, et al. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers. Antivir Ther. 2005;7:803-810.
    • (2005) Antivir Ther , vol.7 , pp. 803-810
    • Bittner, B.1    Riek, M.2    Holmes, B.3
  • 33
    • 1542409142 scopus 로고    scopus 로고
    • A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients
    • McCallister S, Valdez H, Curry K, et al. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;4:376-382.
    • (2004) J Acquir Immune Defic Syndr , vol.4 , pp. 376-382
    • McCallister, S.1    Valdez, H.2    Curry, K.3
  • 34
    • 43649102537 scopus 로고    scopus 로고
    • A review of the pharmacokinetics of abacavir
    • Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;6:351-371.
    • (2008) Clin Pharmacokinet , vol.6 , pp. 351-371
    • Yuen, G.J.1    Weller, S.2    Pakes, G.E.3
  • 35
    • 17144399255 scopus 로고    scopus 로고
    • Pharmacokinetic profiling and bioequivalence evaluation of 2 lamivudine tablet formulations after single oral administration in healthy human Indian volunteers
    • Narang VS, Lulla A, Malhotra G, et al. Pharmacokinetic profiling and bioequivalence evaluation of 2 lamivudine tablet formulations after single oral administration in healthy human Indian volunteers. J Acquir Immune Defic Syndr. 2005;5:566-569.
    • (2005) J Acquir Immune Defic Syndr , vol.5 , pp. 566-569
    • Narang, V.S.1    Lulla, A.2    Malhotra, G.3
  • 36
    • 12944284655 scopus 로고    scopus 로고
    • Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers
    • Droste JA, Verweij-van Wissen CP, Kearney BP, et al. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2005;2:680-684.
    • (2005) Antimicrob Agents Chemother , vol.2 , pp. 680-684
    • Droste, J.A.1    Verweij-Van Wissen, C.P.2    Kearney, B.P.3
  • 37
    • 33646404628 scopus 로고    scopus 로고
    • Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects
    • Marier JF, Manthos H, Kebir S, et al. Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects. Int J Clin Pharmacol Ther. 2006;5:240-246.
    • (2006) Int J Clin Pharmacol Ther , vol.5 , pp. 240-246
    • Marier, J.F.1    Manthos, H.2    Kebir, S.3
  • 38
    • 37349046483 scopus 로고    scopus 로고
    • Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects
    • Liu P, Foster G, LaBadie RR, et al. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol. 2008;1:73-84.
    • (2008) J Clin Pharmacol , vol.1 , pp. 73-84
    • Liu, P.1    Foster, G.2    Labadie, R.R.3
  • 39
    • 34548515995 scopus 로고    scopus 로고
    • Bioequivalence study of two nevirapine tablet formulations in human-immunodeficiency-virus-infected patients
    • Tarinas A, Tapanes RD, Gonzalez D, et al. Bioequivalence study of two nevirapine tablet formulations in human-immunodeficiency-virus-infected patients. Farm Hosp. 2007;3:165-168.
    • (2007) Farm Hosp , vol.3 , pp. 165-168
    • Tarinas, A.1    Tapanes, R.D.2    Gonzalez, D.3
  • 40
    • 46349097362 scopus 로고    scopus 로고
    • Reviews of anti-infective agents: Maraviroc: The first of a new class of antiretroviral agents
    • MacArthur RD, Novak RM. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis. 2008;2: 236-241.
    • (2008) Clin Infect Dis , vol.2 , pp. 236-241
    • MacArthur, R.D.1    Novak, R.M.2
  • 41
    • 33845907631 scopus 로고    scopus 로고
    • A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background
    • Haan C, Behrmann I. A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. J Immunol Methods. 2007;1-2:11-19.
    • (2007) J Immunol Methods , vol.1-2 , pp. 11-19
    • Haan, C.1    Behrmann, I.2
  • 42
    • 13444269543 scopus 로고    scopus 로고
    • Haploview: Analysis and visualization of LD and haplotype maps
    • Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;2:263-265.
    • (2005) Bioinformatics , vol.2 , pp. 263-265
    • Barrett, J.C.1    Fry, B.2    Maller, J.3
  • 43
    • 4444367508 scopus 로고    scopus 로고
    • Haplotype reconstruction from genotype data using Imperfect Phylogeny
    • Halperin E, Eskin E. Haplotype reconstruction from genotype data using Imperfect Phylogeny. Bioinformatics. 2004;12:1842-1849.
    • (2004) Bioinformatics , vol.12 , pp. 1842-1849
    • Halperin, E.1    Eskin, E.2
  • 44
    • 70349432367 scopus 로고    scopus 로고
    • CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti
    • Leger P, Dillingham R, Beauharnais CA, et al. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis. 2009;6:955-964.
    • (2009) J Infect Dis , vol.6 , pp. 955-964
    • Leger, P.1    Dillingham, R.2    Beauharnais, C.A.3
  • 45
    • 65649091303 scopus 로고    scopus 로고
    • Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans
    • Haas DW, Gebretsadik T, Mayo G, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis. 2009;6:872-880.
    • (2009) J Infect Dis , vol.6 , pp. 872-880
    • Haas, D.W.1    Gebretsadik, T.2    Mayo, G.3
  • 46
    • 33646510761 scopus 로고    scopus 로고
    • Screening for polymorphisms in the PXR gene in a Dutch population
    • Bosch TM, Deenen M, Pruntel R, et al. Screening for polymorphisms in the PXR gene in a Dutch population. Eur J Clin Pharmacol. 2006;5:395-399.
    • (2006) Eur J Clin Pharmacol , vol.5 , pp. 395-399
    • Bosch, T.M.1    Deenen, M.2    Pruntel, R.3
  • 47
    • 0036219998 scopus 로고    scopus 로고
    • Common allelic variants of cytochrome P4503A4 and their prevalence in different populations
    • Lamba JK, Lin YS, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 2002;2:121-132.
    • (2002) Pharmacogenetics , vol.2 , pp. 121-132
    • Lamba, J.K.1    Lin, Y.S.2    Thummel, K.3
  • 48
    • 0035197548 scopus 로고    scopus 로고
    • Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos
    • Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001;3:825-831.
    • (2001) J Pharmacol Exp Ther , vol.3 , pp. 825-831
    • Dai, D.1    Tang, J.2    Rose, R.3
  • 49
    • 1642457182 scopus 로고    scopus 로고
    • Identification of a novel polymorphic enhancer of the human CYP3A4 gene
    • Matsumura K, Saito T, Takahashi Y, et al. Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol Pharmacol. 2004;2:326-334.
    • (2004) Mol Pharmacol , vol.2 , pp. 326-334
    • Matsumura, K.1    Saito, T.2    Takahashi, Y.3
  • 51
    • 27544486754 scopus 로고    scopus 로고
    • Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles
    • Rodriguez-Antona C, Sayi JG, Gustafsson LL, et al. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun. 2005;1:299-305.
    • (2005) Biochem Biophys Res Commun , vol.1 , pp. 299-305
    • Rodriguez-Antona, C.1    Sayi, J.G.2    Gustafsson, L.L.3
  • 52
    • 41149092923 scopus 로고    scopus 로고
    • Impact of CYP2B6 983T.C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
    • Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T.C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008;4: 914-918.
    • (2008) J Antimicrob Chemother , vol.4 , pp. 914-918
    • Wyen, C.1    Hendra, H.2    Vogel, M.3
  • 53
    • 58349108089 scopus 로고    scopus 로고
    • Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America
    • Kosoy R, Nassir R, Tian C, et al. Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat. 2009;1:69-78.
    • (2009) Hum Mutat , vol.1 , pp. 69-78
    • Kosoy, R.1    Nassir, R.2    Tian, C.3
  • 54
    • 49949084478 scopus 로고    scopus 로고
    • Factors influencing efavirenz and nevirapine plasma concentration: Effect of ethnicity, weight and co-medication
    • Stohr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther. 2008;5:675-685.
    • (2008) Antivir Ther , vol.5 , pp. 675-685
    • Stohr, W.1    Back, D.2    Dunn, D.3
  • 55
    • 40549097017 scopus 로고    scopus 로고
    • Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: Results of CPCRA 058 (FIRST Study)
    • Tedaldi EM, Absalon J, Thomas AJ, et al. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr. 2008;4:441-448.
    • (2008) J Acquir Immune Defic Syndr , vol.4 , pp. 441-448
    • Tedaldi, E.M.1    Absalon, J.2    Thomas, A.J.3
  • 56
    • 0035933511 scopus 로고    scopus 로고
    • The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity
    • Watkins RE, Wisely GB, Moore LB, et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science. 2001;5525:2329-2333.
    • (2001) Science , vol.5525 , pp. 2329-2333
    • Watkins, R.E.1    Wisely, G.B.2    Moore, L.B.3
  • 57
    • 33644588715 scopus 로고    scopus 로고
    • Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz
    • Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics. 2006;3:191-198.
    • (2006) Pharmacogenet Genomics , vol.3 , pp. 191-198
    • Wang, J.1    Sonnerborg, A.2    Rane, A.3
  • 58
    • 0032766430 scopus 로고    scopus 로고
    • Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene
    • Kawamoto T, Sueyoshi T, Zelko I, et al. Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol. 1999;9:6318-6322.
    • (1999) Mol Cell Biol , vol.9 , pp. 6318-6322
    • Kawamoto, T.1    Sueyoshi, T.2    Zelko, I.3
  • 59
    • 66649134127 scopus 로고    scopus 로고
    • Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay
    • Kozawa M, Honma M, Suzuki H. Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay. Drug Metab Dispos. 2009;6:1234-1241.
    • (2009) Drug Metab Dispos , vol.6 , pp. 1234-1241
    • Kozawa, M.1    Honma, M.2    Suzuki, H.3
  • 60
    • 34248573947 scopus 로고    scopus 로고
    • Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice
    • Molto J, Blanco A, Miranda C, et al. Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol. 2007;6:715-721.
    • (2007) Br J Clin Pharmacol , vol.6 , pp. 715-721
    • Molto, J.1    Blanco, A.2    Miranda, C.3
  • 61
    • 9144262579 scopus 로고    scopus 로고
    • CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation
    • Murayama N, Nakamura T, Saeki M, et al. CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation. Drug Metab Pharmacokinet. 2002;2:150-156.
    • (2002) Drug Metab Pharmacokinet , vol.2 , pp. 150-156
    • Murayama, N.1    Nakamura, T.2    Saeki, M.3
  • 62
    • 60349106806 scopus 로고    scopus 로고
    • The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density
    • Kang YS, Park SY, Yim CH, et al. The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther. 2009;3: 312-318.
    • (2009) Clin Pharmacol Ther , vol.3 , pp. 312-318
    • Kang, Y.S.1    Park, S.Y.2    Yim, C.H.3
  • 63
    • 0034959461 scopus 로고    scopus 로고
    • Identification and functional characterization of eight CYP3A4 protein variants
    • Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics. 2001;5:447-458.
    • (2001) Pharmacogenetics , vol.5 , pp. 447-458
    • Eiselt, R.1    Domanski, T.L.2    Zibat, A.3
  • 65
    • 84856916661 scopus 로고    scopus 로고
    • Accessed November 17, 2009
    • GeneCards Human Gene Database. Available at: http://www.genecards.org/ cgi-bin/carddisp.pl?gene=CYP3A4&search=rs4987159&snp=322&snp-sort- mode=140#snp. Accessed November 17, 2009.
    • GeneCards Human Gene Database
  • 66
    • 33947382259 scopus 로고    scopus 로고
    • Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals
    • Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther. 2007;4:557-566.
    • (2007) Clin Pharmacol Ther , vol.4 , pp. 557-566
    • Rotger, M.1    Tegude, H.2    Colombo, S.3
  • 67
    • 33847348828 scopus 로고    scopus 로고
    • Does tenofovir influence efavirenz pharmacokinetics?
    • Rotger M, Colombo S, Furrer H, et al. Does tenofovir influence efavirenz pharmacokinetics? Antivir Ther. 2007;1:115-118.
    • (2007) Antivir Ther , vol.1 , pp. 115-118
    • Rotger, M.1    Colombo, S.2    Furrer, H.3
  • 68
    • 35348923463 scopus 로고    scopus 로고
    • Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26
    • Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis. 2007;9:1230-1237.
    • (2007) Clin Infect Dis , vol.9 , pp. 1230-1237
    • Gatanaga, H.1    Hayashida, T.2    Tsuchiya, K.3
  • 69
    • 0037378823 scopus 로고    scopus 로고
    • Functional characterization of cytochrome P450 2B6 allelic variants
    • Jinno H, Tanaka-Kagawa T, Ohno A, et al. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos. 2003;4: 398-403.
    • (2003) Drug Metab Dispos , vol.4 , pp. 398-403
    • Jinno, H.1    Tanaka-Kagawa, T.2    Ohno, A.3
  • 70
    • 0142188754 scopus 로고    scopus 로고
    • Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
    • Kirchheiner J, Klein C, Meineke I, et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003;10:619-626.
    • (2003) Pharmacogenetics , vol.10 , pp. 619-626
    • Kirchheiner, J.1    Klein, C.2    Meineke, I.3
  • 71
    • 33750312905 scopus 로고    scopus 로고
    • Multilocus genetic interactions and response to efavirenz-containing regimens: An adult AIDS clinical trials group study
    • Motsinger AA, Ritchie MD, Shafer RW, et al. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics. 2006;11: 837-845.
    • (2006) Pharmacogenet Genomics , vol.11 , pp. 837-845
    • Motsinger, A.A.1    Ritchie, M.D.2    Shafer, R.W.3
  • 72
    • 67649126219 scopus 로고    scopus 로고
    • Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART
    • Bertrand J, Treluyer JM, Panhard X, et al. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Eur J Clin Pharmacol. 2009;7:667-678.
    • (2009) Eur J Clin Pharmacol , vol.7 , pp. 667-678
    • Bertrand, J.1    Treluyer, J.M.2    Panhard, X.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.